Sentinel Node Biopsy Market Research Report Information By Product (Breast Localization Wire, Tissue Marker, Gamma Probe and Drainage Catheters), By Indication (Breast Cancer, Melanoma, Colon Cancer and Esophageal Cancer), By End-User (Hospitals & Clinics and Diagnostic Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Sentinel Node Biopsy Market Overview

Sentinel Node Biopsy Market Size was valued at USD 0.5 Billion in 2022. The sentinel node biopsy market industry is projected to grow from USD 0.524 Billion in 2023 to USD 0.769 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.90% during the forecast period (2023 - 2032). The  market for sentinel node biopsies is steadily expanding, mostly as a result of the rising incidence of certain cancers, including melanoma, colon, breast, esophageal, head and neck, and others. The changing lifestyle brought on by increasing urbanization and industrialization are further market drivers boosting the market's expansion. ly improving economic conditions are driving the sentinel node biopsy market's expansion and opening up access to higher standards of living and better healthcare.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Sentinel Node Biopsy Market Trends

• Rise in cancer incidence is driving the market growth

A primary market driver for sentinel node biopsy is the rise in cancer incidence. The burden of cancer on healthcare systems, economies, and people as a whole makes it a serious worldwide health concern. According to the World Health Organisation (WHO), the burden of cancer will continue to grow worldwide in the upcoming years. In order to increase patient survival rates and optimize treatment outcomes, this growing burden highlights the need for efficient cancer management options, such as SNB. With its incidence rising gradually over the world, cancer continues to be a significant  health concern. The ageing of the population, lifestyle modifications, environmental exposures, and genetic predisposition are some of the factors that contribute to the increase in cancer incidences. Effective diagnostic and staging techniques, like SNB, are increasingly important as cancer prevalence rises in order to inform the selection of the most suitable treatments. Changing lifestyles, such as sedentary behaviors, unhealthy eating habits, and greater exposure to environmental toxins, also have a role in the rising incidence of cancer. There are several known risk factors for different types of cancer, including smoking, poor diets, chemical exposure, pollution, and UV radiation.

The sentinel node biopsy (SNB) industry is expanding as a result of technological improvements. These developments help to increase the precision, effectiveness, and safety of SNB operations, as well as patient outcomes and the range of cancer types for which SNB can be used. SNB operations have undergone a revolution thanks to advanced imaging technology. The sentinel lymph node can be precisely identified by the nuclear medicine imaging technique known as lymphoscintigraphy, which makes use of radioactive tracers to visualize lymphatic drainage routes.

Thus, driving the sentinel node biopsy market revenue.

Sentinel Node Biopsy Market Segment Insights

Sentinel Node Biopsy Product Insights

The  sentinel node biopsy market segmentation, based on product includes Breast Localization Wire, Tissue Marker, Gamma Probe and Drainage Catheters. The gamma probe segment dominated the market. Handheld instruments known as intraoperative gamma probes are used in surgery to quickly and accurately quantify the gamma radiation that radioactive tracers emit. These probes lower the possibility of unneeded lymph node dissection by assisting surgeons in precisely locating and removing the sentinel lymph node. They immediately give comments and direction throughout the process, enhancing SNB's accuracy.

Sentinel Node Biopsy Indication Insights

The  sentinel node biopsy market segmentation, based on indication, includes Breast Cancer, Melanoma, Colon Cancer and Esophageal Cancer. The breast cancer category generated the most income. The market for sentinel node biopsy is largely dominated by breast cancer. Sentinel node biopsy is a critical technique in enhancing patient outcomes since early detection and precise staging are essential for breast cancer treatment. Furthermore, the melanoma category is anticipated to grow at the fastest rate over the forecast period. The care of melanoma, a kind of skin cancer, depends heavily on sentinel node biopsy. The process aids in determining the extent of the malignancy and in selecting the best course of treatment.

Sentinel Node Biopsy End-User Insights

The  sentinel node biopsy market segmentation, based on end-user includes Hospitals & Clinics and Diagnostic Centers. The hospitals & clinics segment dominated the market. Sentinel node biopsy methods are frequently used in hospitals and clinics. They have well-established surgical departments with the ability to do SNB procedures, and they offer complete cancer treatment services. Hospitals frequently have cutting-edge imaging equipment like intraoperative gamma probes and lymphoscintigraphy, which helps with precisely identifying and localizing sentinel lymph nodes.

Figure 1  Sentinel Node Biopsy Market, by Distribution channel, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Sentinel Node Biopsy Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American sentinel node biopsy market area will dominate this market. The market for sentinel node biopsy, ly, is driven by the growing number of market players providing biopsy devices and instruments. The region's market expansion is supported by elements including the extensive and early use of medical technology for improving medical equipment, the rising level of governmental support for R&D initiatives, and the high costs of health care. Additionally, the availability of high-quality care, the rising prevalence of breast cancer and the expanding number of women with breast problems all contribute to the growth of the regional market. The market is anticipated to generate the largest revenue pocket over the review period due to the ongoing advances made by businesses involved in cancer diagnostics.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  SENTINEL NODE BIOPSY MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe sentinel node biopsy market accounts for the second-largest market share accounted for by the growing focus on the development of advanced diagnostic instruments. Additionally, factors boosting the growth of the regional market include increasing government support with higher funding for R&D efforts in the field of oncology and the rising number of specialist services provided by different healthcare providers. A growing need for cancer diagnosis has caused Germany to dominate the European market for sentinel node biopsies. France and the U.K., on the other hand, take second and third place, respectively, due to the availability of tertiary care facilities in these nations and rising healthcare costs. Further, the German sentinel node biopsy market held the largest market share, and the UK sentinel node biopsy market was the fastest growing market in the European region

The Asia-Pacific Sentinel node biopsy Market is expected to grow at the fastest CAGR from 2023 to 2032. Breast cancer cases are on the rise, which is a major reason in the market's expansion. Additionally, the market expansion in the APAC region is being fueled by factors like the rising demand for high-quality medical devices and the swiftly evolving healthcare technology, which is resulting in an increase in the use of advanced biopsy equipment. The highly skilled workforce in China and India, as well as the rising need for biopsy procedures in hospitals and specialist care facilities, present tremendous growth potential.  Furthermore, rising chronic disease rates, an increase in the number of women experiencing reproductive problems, and rising surgical procedure costs in developing nations across APAC all contribute to the expansion of the regional market. Moreover, China’s sentinel node biopsy market held the largest market share, and the Indian sentinel node biopsy market was the fastest growing market in the Asia-Pacific region.

Sentinel Node Biopsy Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the sentinel node biopsy market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, sentinel node biopsy industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  sentinel node biopsy industry to benefit clients and increase the market sector. In recent years, the sentinel node biopsy industry has offered some of the most significant advantages to market. Major players in the sentinel node biopsy market attempting to increase market demand by investing in research and development operations include Devicor Medical Products Inc., part of Leica Biosystems. (Germany), C. R. Bard Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies Inc. (U.S.) and Navidea Biopharmaceuticals Inc.(U.S.).

A biopharmaceutical business called Navidea Biopharmaceuticals Inc. creates precise immunodiagnostic and immunotherapeutic drugs. Its pipeline items include NAV4694 for Alzheimer's Disease and Tc99m tilmanocept for Kaposi's sarcoma, NAS, cardiovascular disorders, sentinal node biopsies, and solid tumour lymphatic mapping. Utilising the Manocept platform, Navidea creates a variety of precision-targeted products to enhance patient care by locating illness pathways and sites and facilitating accurate clinical judgement and diagnosis. The business is present in both the US and the UK. The headquarters of Navidea are in Dublin, Ohio, in the US.

KUBTEC is working to change the way breast cancer surgery is now done and to cut down on the excessive number of re-excision procedures. With the help of ongoing research and development of our unique 3D tomosynthesis technology, KUBTEC is giving surgeons immediate access to surgical margin visualization in the operating room, assisting in lowering re-excision rates, preserving healthy breast tissue, and ultimately improving patient outcomes.

Key Companies in the sentinel node biopsy market include

• Devicor Medical Products Inc.


• part of Leica Biosystems. (Germany)


• R. Bard Inc. (U.S.)


• INTRAMEDICAL IMAGING LLC (U.S.)


• Hilfe Engineering Corporation (India)


• Surgic Eye (Germany)


• KUB Technologies Inc. (U.S.)


• Navidea Biopharmaceuticals Inc.(U.S.)

Sentinel Node Biopsy Industry Developments

January 2019  The clinical test result of Castle Biosciences, Inc.'s (the US) melanoma test, the DecisionDx, which helps doctors decide whether to perform a sentinel lymph node biopsy, a surgical procedure that aids in melanoma staging, was published. This company specializes in the diagnosis of skin cancer and provides personalized genomic information to help doctors make better cancer management decisions.

Sentinel Node Biopsy Market Segmentation

Sentinel Node Biopsy Product Outlook (USD Billion, 2018-2032)

• Breast Localization Wire


• Tissue Marker


• Gamma Probe


• Drainage Catheters

Sentinel Node Biopsy Indication Outlook (USD Billion, 2018-2032)

• Breast Cancer


• Melanoma


• Colon Cancer


• Esophageal Cancer

Sentinel Node Biopsy End-User Outlook (USD Billion, 2018-2032)

• Hospitals & Clinics


• Diagnostic Centers

Sentinel Node Biopsy Regional Outlook (USD Billion, 2018-2032)

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

Sentinel Node Biopsy Report Scope

Report Attribute/Metric	Details
Market Size 2022	USD 0.5 Billion
Market Size 2023	USD 0.524 Billion
Market Size 2032	USD 0.769 Billion
Compound Annual Growth Rate (CAGR)	4.90% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product, Indication, End-User and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Devicor Medical Products Inc., part of Leica Biosystems. (Germany), C. R. Bard Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies Inc. (U.S.) and Navidea Biopharmaceuticals Inc.(U.S.)
Key Market Opportunities	Increasing demand for new products and accessories with advent of technology
Key Market Dynamics	Rise in cancer incidence is driving the market growth Increasing number of women health problems

Frequently Asked Questions (FAQ) :